M&A Deal Summary

Shire Acquires Foresight Biotherapeutics

On August 3, 2015, Shire acquired life science company Foresight Biotherapeutics for 300M USD

Acquisition Highlights
  • This is Shire’s 13th transaction in the Life Science sector.
  • This is Shire’s 7th largest (disclosed) transaction.
  • This is Shire’s 11th transaction in the United States.
  • This is Shire’s 1st transaction in New York.

M&A Deal Summary
Date 2015-08-03
Target Foresight Biotherapeutics
Sector Life Science
Buyer(s) Shire
Deal Type Add-on Acquisition
Deal Value 300M USD

Target

Foresight Biotherapeutics

New York, New York, United States
Foresight Biotherapeutics, Inc. is a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shire

Dublin, Ireland
Category Company
Founded 1986
Sector Life Science
Employees5,548
Revenue 6.4B USD (2015)
DESCRIPTION

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

DEAL STATS #
Overall 13 of 16
Sector (Life Science) 13 of 15
Type (Add-on Acquisition) 12 of 14
State (New York) 1 of 1
Country (United States) 11 of 13
Year (2015) 3 of 4
Size (of disclosed) 7 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-24 Meritage Pharma

San Diego, California, United States

Meritage Pharma, Inc. is a provider of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus.

Buy $70M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-02 Dyax

Burlington, Massachusetts, United States

Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.

Buy $5.9B
Mergr

Product

Company

Legal